6.625

0.89% -0.115

Vir Biotechnology Inc (VIR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VIR? Forum Prognose

Schlusskurs vom Vortag:

$6.74

Offen:

$6.74

24-Stunden-Volumen:

112.29K

Relative Volume:

0.12

Marktkapitalisierung:

$953.02M

Einnahmen:

$62.04M

Nettoeinkommen (Verlust:

$-533.34M

KGV:

-1.4755

EPS:

-4.49

Netto-Cashflow:

$-473.07M

1W Leistung:

-22.69%

1M Leistung:

-12.68%

6M Leistung:

-34.57%

1J Leistung:

-29.16%

1-Tages-Spanne:

$6.57

$6.81

1-Wochen-Bereich:

$6.57

$8.71

52-Wochen-Spanne:

$6.57

$13.09

Vir Biotechnology Inc Stock (VIR) Company Profile

Firmenname

Vir Biotechnology Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

415-906-4324

Adresse

1800 OWENS STREET, SAN FRANCISCO, CA

Mitarbeiter

587

Twitter

@Vir_Biotech

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

VIR's Discussions on Twitter

Vergleichen Sie VIR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VIR	6.6314	953.02M	62.04M	-533.34M	-473.07M	-4.49
VRTX	446.01	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.92	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.24	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.28	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.39	24.49B	3.30B	-501.07M	1.03B	11.54

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2023-09-08	Herabstufung	BofA Securities	Buy → Neutral
2023-03-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-02-21	Hochstufung	Goldman	Neutral → Buy
2023-01-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Eingeleitet	SVB Leerink	Outperform
2022-09-09	Eingeleitet	Morgan Stanley	Underweight
2022-03-03	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-12-21	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-10-25	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-01-27	Herabstufung	JP Morgan	Neutral → Underweight
2021-01-20	Bestätigt	H.C. Wainwright	Buy
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-09-14	Hochstufung	Goldman	Neutral → Buy
2020-09-11	Hochstufung	JP Morgan	Underweight → Neutral
2020-08-20	Eingeleitet	Needham	Buy
2020-03-19	Herabstufung	JP Morgan	Neutral → Underweight
2020-03-13	Herabstufung	Goldman	Buy → Neutral
2020-02-27	Herabstufung	Robert W. Baird	Neutral → Underperform
2020-02-04	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-14	Eingeleitet	Robert W. Baird	Neutral
2019-11-05	Eingeleitet	Barclays	Overweight
2019-11-05	Eingeleitet	Cowen	Outperform
2019-11-05	Eingeleitet	Goldman	Buy
2019-11-05	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

Nov 20, 2024

Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - BioSpace

Nov 19, 2024

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - BioSpace

Nov 19, 2024

Nov 18, 2024

VIRVir Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan

Nov 18, 2024

Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial | VIR Stock News - StockTitan

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments - Investing.com

Nov 18, 2024

EMA grants orphan drug status to Vir Biotech hepatitis treatments By Investing.com - Investing.com Canada

Nov 18, 2024

Vir Biotechnology (VIR) Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - StreetInsider.com

Nov 18, 2024

Vir Biotechnology Secures Key EU Orphan Drug Status for Hepatitis Delta Treatment | VIR Stock News - StockTitan

Nov 18, 2024

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD the Liver Meeting - Marketscreener.com

Nov 18, 2024

Nov 16, 2024

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.4%Here's Why - MarketBeat

Nov 16, 2024

Nov 15, 2024

(VIR) Proactive Strategies - Stock Traders Daily

Nov 15, 2024

What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance

Nov 15, 2024

Promising hepatitis B treatment data presented by Vir Biotechnology - Investing.com

Nov 15, 2024